← Leaderboards
Alexandros Makriyannis
University Of Connecticut Storrs
$48,379,340
Attributed
$56,116,749
Total exposure
36
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$79,204,308 · 37
By mechanism
P01$29,688,465 · 12
R01$22,819,588 · 9
R37$10,789,769 · 2
U01$7,620,056 · 1
T32$5,302,139 · 2
K05$1,266,516 · 1
Top collaborators
- Raymond C Stevens7 shared
- Jack Bergman6 shared
- Laura M Bohn5 shared
- Madhavan P Nair5 shared
- Raymond G Booth4 shared
- Carol A Paronis4 shared
- Vsevolod Katritch3 shared
- Madepalli Krishnappa Lakshmana1 shared
Most similar at University Of Connecticut Storrs
Same institution · by research overlap
- Xiang-Qun Xie$8,062,308
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsCannabinoidsLigandsDesignAgonistBaseIn VivoAnalogCannabinoid ReceptorLaboratoriesAddictionAffinityPropertyAnandamideIn VitroEndocannabinoidsPreparationStructureResponseCnr1 GeneProgramsComputer SimulationLiquid Chromatography Mass SpectrometryBrain
Grant awards (187)
Endocannabinoid Active Sites as Therapeutic Targets$1,438,465
P01 · FY2025 · DA · contact PI
Project 1 - Design and Synthesis of Novel Functionally Selective CB1 and CB2 Cannabinergic Ligands$624,054
P01 · FY2025 · DA · contact PI
Training Program on Development of Medications for Substance Use Disorder$347,268
T32 · FY2025 · DA · contact PI
Administrative Core$89,914
P01 · FY2025 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2025 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,444,077
P01 · FY2024 · DA · contact PI
CB1 Neutral Antagonists for Alcohol Use Disorder$1,179,935
U01 · FY2024 · AA · contact PI
Project 1 - Design and Synthesis of Novel Functionally Selective CB1 and CB2 Cannabinergic Ligands$625,740
P01 · FY2024 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$370,347
R01 · FY2024 · DA
Training Program on Development of Medications for Substance Use Disorder$224,689
T32 · FY2024 · DA · contact PI
Administrative Core$90,015
P01 · FY2024 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2024 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,434,681
P01 · FY2023 · DA · contact PI
CB1 Neutral Antagonists for Alcohol Use Disorder$1,163,887
U01 · FY2023 · AA · contact PI
CB1 Neutral Antagonists for Alcohol Use Disorder$797,500
U01 · FY2023 · AA · contact PI
Project 1 - Design and Synthesis of Novel Functionally Selective CB1 and CB2 Cannabinergic Ligands$622,643
P01 · FY2023 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$370,610
R01 · FY2023 · DA
Training Program on Development of Medications for Substance Use Disorder$339,036
T32 · FY2023 · DA · contact PI
Administrative Core$89,636
P01 · FY2023 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2023 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,477,010
P01 · FY2022 · DA · contact PI
CB1 Neutral Antagonists for Alcohol Use Disorder$1,218,797
U01 · FY2022 · AA · contact PI
Project 1 - Design and Synthesis of Novel Functionally Selective CB1 and CB2 Cannabinergic Ligands$628,553
P01 · FY2022 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$370,861
R01 · FY2022 · DA
Antidotes for Acute Cannabinoid Intoxication$368,784
R33 · FY2022 · DA · contact PI
Training Program on Development of Medications for Substance Use Disorder$318,803
T32 · FY2022 · DA · contact PI
Administrative Core$89,689
P01 · FY2022 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2022 · DA · contact PI
CB1 Neutral Antagonists for Alcohol Use Disorder$1,605,663
U01 · FY2021 · AA · contact PI
Structure and Function of CB2 Receptor$763,601
R01 · FY2021 · DA · contact PI
Antidotes for Acute Cannabinoid Intoxication$378,213
R33 · FY2021 · DA · contact PI
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$371,100
R01 · FY2021 · DA
Effect of a potent and metabolically stable endocannabinoid receptor agonist on inflammasome-induced neuroinflammation in a comorbid mouse model of Alzheimer's disease and HIV$364,202
R01 · FY2021 · DA
CB1/CB2 Cannabinoid Ligands for HIV Neuropathic Pain$120,191
P01 · FY2021 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2021 · DA · contact PI
CB1 Neutral Antagonists for Alcohol Use Disorder$1,654,274
U01 · FY2020 · AA · contact PI
Structure and Function of CB2 Receptor$763,601
R01 · FY2020 · DA · contact PI
Structure Function of CB1 Cannabinoid Receptor$716,981
R01 · FY2020 · DA
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid$383,202
R01 · FY2020 · DA
CB1/CB2 Cannabinoid Ligands for HIV Neuropathic Pain$120,191
P01 · FY2020 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2020 · DA · contact PI
Structure and Function of CB2 Receptor$763,601
R01 · FY2019 · DA · contact PI
Structure Function of CB1 Cannabinoid Receptor$716,981
R01 · FY2019 · DA · contact PI
Antidotes for Acute Cannabinoid Intoxication$230,994
R21 · FY2019 · DA · contact PI
Medications for Synthetic Cannabinoid Abuse$225,000
R41 · FY2019 · DA · contact PI
Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases$224,999
R41 · FY2019 · DK · contact PI
CB1/CB2 Cannabinoid Ligands for HIV Neuropathic Pain$85,564
P01 · FY2019 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2019 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,266,254
P01 · FY2018 · DA · contact PI
Structure and Function of CB2 Receptor$763,601
R01 · FY2018 · DA · contact PI
Structure Function of CB1 Cannabinoid Receptor$716,981
R01 · FY2018 · DA
Cannabinergic Ligands and Active Sites- Project 1$536,428
P01 · FY2018 · DA · contact PI
CB1/CB2 Cannabinoid Ligands for HIV Neuropathic Pain$120,191
P01 · FY2018 · DA · contact PI
Core A Administrative$87,758
P01 · FY2018 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2018 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,266,254
P01 · FY2017 · DA · contact PI
Structure and Function of CB2 Receptor$877,195
R01 · FY2017 · DA · contact PI
Structure Function of CB1 Cannabinoid Receptor$716,981
R01 · FY2017 · DA
Cannabinergic Ligands and Active Sites- Project 1$536,428
P01 · FY2017 · DA · contact PI
Molecular Basis of Cannabinoid Activity$517,387
R01 · FY2017 · DA · contact PI
CB1/CB2 Cannabinoid Ligands for HIV Neuropathic Pain$133,566
P01 · FY2017 · DA · contact PI
Core A Administrative$87,758
P01 · FY2017 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2017 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,253,591
P01 · FY2016 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$743,185
R37 · FY2016 · DA · contact PI
Structure Function of CB1 Cannabinoid Receptor$726,665
R01 · FY2016 · DA
Cannabinergic Ligands and Active Sites- Project 1$531,063
P01 · FY2016 · DA · contact PI
Molecular Basis of Cannabinoid Activity$512,213
R01 · FY2016 · DA · contact PI
Endogenous/exogenous cannabinoids: A comparison$237,075
R01 · FY2016 · DA · contact PI
Core A Administrative$86,882
P01 · FY2016 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2016 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,251,775
P01 · FY2015 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$739,906
R37 · FY2015 · DA · contact PI
Cannabinergic Ligands and Active Sites- Project 1$531,148
P01 · FY2015 · DA · contact PI
Molecular Basis of Cannabinoid Activity$509,626
R01 · FY2015 · DA · contact PI
Core A Administrative$86,005
P01 · FY2015 · DA · contact PI
Chemistry and Pharmacology of Drugs of Abuse Annual Symposium$25,000
R13 · FY2015 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,281,665
P01 · FY2014 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$733,538
R37 · FY2014 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$524,102
R01 · FY2014 · DA
Cannabinergic Ligands and Active Sites- Project 1$516,463
P01 · FY2014 · DA · contact PI
Molecular Basis of Cannabinoid Activity$483,515
R01 · FY2014 · DA · contact PI
Core A Administrative$77,995
P01 · FY2014 · DA · contact PI
Molecular Basis of Cannabinoid Activity$36,049
R01 · FY2014 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$687,900
R37 · FY2013 · DA · contact PI
Novel Medications for Cannabis Dependence$539,300
R01 · FY2013 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$529,932
R01 · FY2013 · DA
Molecular Basis of Cannabinoid Activity$483,666
R01 · FY2013 · DA · contact PI
Training Program in Medications Development for Drugs of Abuse (Institutional Rut$96,804
T32 · FY2013 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$699,373
R37 · FY2012 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$564,664
R01 · FY2012 · DA
Novel Medications for Cannabis Dependence$562,171
R01 · FY2012 · DA · contact PI
Cannabinergic Ligands and Drugs$419,196
R01 · FY2012 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,051,850
P01 · FY2011 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$660,516
R37 · FY2011 · DA · contact PI
Novel Medications for Cannabis Dependence$567,200
R01 · FY2011 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$551,624
R01 · FY2011 · DA
Training Program in Medications Development for Drugs of Abuse (Institutional Rut$388,839
T32 · FY2011 · DA · contact PI
Cannabinergic Ligands and Drugs$351,660
R01 · FY2011 · DA · contact PI
Cannabinergic Ligands and Drugs$74,640
R01 · FY2011 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$46,633
R37 · FY2011 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$20,520
R01 · FY2011 · DA
Endocannabinoid Active Sites as Therapeutic Targets$1,053,894
P01 · FY2010 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$661,115
R37 · FY2010 · DA · contact PI
Candidate Medications for Cannabis Addiction: FAAH Inhibitors$577,205
R01 · FY2010 · DA
Novel Medications for Cannabis Dependence$566,098
R01 · FY2010 · DA · contact PI
Training Program in Medications Development for Drugs of Abuse (Institutional Rut$382,143
T32 · FY2010 · DA · contact PI
Cannabinergic Ligands and Drugs$355,212
R01 · FY2010 · DA · contact PI
Studies on Cannabinoid Effects and Cannabimimetic Drugs$119,264
K05 · FY2010 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$43,680
R37 · FY2010 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,097,826
P01 · FY2009 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$691,419
R37 · FY2009 · DA · contact PI
Novel Medications for Cannabis Dependence$580,803
R01 · FY2009 · DA · contact PI
Training Program in Medications Development for Drugs of Abuse (Institutional Rut$391,061
T32 · FY2009 · DA · contact PI
Cannabinergic Ligands and Drugs$358,800
R01 · FY2009 · DA · contact PI
Studies on Cannabinoid Effects and Cannabimimetic Drugs$119,264
K05 · FY2009 · DA · contact PI
Cannabinergic Ligands and Drugs$78,000
R01 · FY2009 · DA · contact PI
Cannabinergic Ligands and Drugs$38,470
R01 · FY2009 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,102,420
P01 · FY2008 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$672,538
R37 · FY2008 · DA · contact PI
Training Program in Medications Development for Drugs of Abuse (Institutional Rut$376,932
T32 · FY2008 · DA · contact PI
Cannabinergic Ligands and Drugs$358,800
R01 · FY2008 · DA · contact PI
Studies on Cannabinoid Effects and Cannabimimetic Drugs$119,264
K05 · FY2008 · DA · contact PI
Administrative Core$32,463
P01 · FY2008 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$32,447
P01 · FY2008 · DA · contact PI
CANNABINOID RECEPTOR AS THERAPEUTIC TARGET$1,102
P41 · FY2008 · RR · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,027,528
P01 · FY2007 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$637,847
R37 · FY2007 · DA · contact PI
Training Program in Medications Development for Drugs of Abuse (Institutional Rut$385,000
T32 · FY2007 · DA · contact PI
Studies on Cannabinoid Effects and Cannabimimetic Drugs$119,264
K05 · FY2007 · DA · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$46,650
P01 · FY2007 · DA · contact PI
Convergent Cannabinoid, Cholinergic and Serotonergic Neurotransmission Identifies$46,650
P01 · FY2007 · DA · contact PI
Cannabinergic Medications for Methamphetamine Addiction$43,960
R37 · FY2007 · DA · contact PI
CANNABINOID RECEPTOR AS THERAPEUTIC TARGET$1,883
P41 · FY2007 · RR · contact PI
MOLECULAR BASIS OF CANNABINOID ACITIVITY$639,858
R37 · FY2006 · DA · contact PI
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$336,069
T32 · FY2006 · DA · contact PI
Cannabinergic Ligands & Drugs$262,093
R01 · FY2006 · DA · contact PI
Studies on Cannabinoid Effects and Cannabimimetic Drugs$119,264
K05 · FY2006 · DA · contact PI
Cannabinergic Ligands & Drugs$61,230
R01 · FY2006 · DA · contact PI
CANNABINOID RECEPTOR AS THERAPEUTIC TARGET$1,233
P41 · FY2006 · RR · contact PI
Endocannabinoid Active Sites as Therapeutic Targets$1,256,605
P01 · FY2005 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$636,769
R37 · FY2005 · DA
Cannabinergic Ligands &Drugs$268,400
R01 · FY2005 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$95,082
T32 · FY2005 · DA
CANNABINOID RECEPTOR AS THERAPEUTIC TARGET$1,190
P41 · FY2005 · RR
Endocannabinoid Active Sites as Therapeutic Targets$1,161,249
P01 · FY2004 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$396,800
T32 · FY2004 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$378,492
R37 · FY2004 · DA
Cannabinergic Ligands &Drugs$251,600
R01 · FY2004 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$188,219
R37 · FY2004 · DA
STUDIES ON CANNABINOID EFFECTS AND CANNABIMIMETIC DRUGS$118,876
K05 · FY2004 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$82,235
T32 · FY2004 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$7,978
R37 · FY2004 · DA
CANNABINOID RECEPTOR AS THERAPEUTIC TARGET$1,178
P41 · FY2004 · RR
Endocannabinoid Active Sites as Therapeutic Targets$906,091
P01 · FY2003 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$458,508
T32 · FY2003 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$448,488
R37 · FY2003 · DA
Cannabinergic Ligands &Drugs$251,600
R01 · FY2003 · DA
Endocannabinoid Active Sites as Therapeutic Targets$146,956
P01 · FY2003 · DA
STUDIES ON CANNABINOID EFFECTS AND CANNABIMIMETIC DRUGS$137,830
K05 · FY2003 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$101,342
R37 · FY2003 · DA
Endocannabinoid Sites as Therapeutic Targets$72,410
P01 · FY2003 · DA
Endocannabinoid Active Sites as Therapeutic Targets$972,428
P01 · FY2002 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$435,425
R37 · FY2002 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$395,086
T32 · FY2002 · DA
DOPAMINE TRANSPORTER LIGANDS AS COCAINE MEDICATIONS$379,839
R01 · FY2002 · DA
Cannabinergic Ligands &Drugs$251,600
R01 · FY2002 · DA
STUDIES ON CANNABINOID EFFECTS AND CANNABIMIMETIC DRUGS$137,830
K05 · FY2002 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$24,566
T32 · FY2002 · DA
CORE--CHEMISTRY, BIOCHEMISTRY, PHARMACOLOGY$1,959
P01 · FY2002 · DA
CANNIBINOID RECEPTOR MOLECULAR PROBES$1,959
P01 · FY2002 · DA
Endocannabinoid Active Sites as Therapeutic Targets$1,045,433
P01 · FY2001 · DA
DOPAMINE TRANSPORTER LIGANDS AS COCAINE MEDICATIONS$368,775
R01 · FY2001 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$361,931
R37 · FY2001 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$259,178
T32 · FY2001 · DA
STUDIES ON CANNABINOID EFFECTS AND CANNABIMIMETIC DRUGS$137,830
K05 · FY2001 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$75,000
R37 · FY2001 · DA
THE CANNABINOID RECEPTOR AS A THERAPEUTIC TARGET$0
P41 · FY2001 · RR
DOPAMINE TRANSPORTER LIGANDS AS COCAINE MEDICATIONS$358,039
R01 · FY2000 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$286,927
R37 · FY2000 · DA
CANNABIMIMETIC LIGANDS AND DRUGS$211,974
R01 · FY2000 · DA
STUDIES ON CANNABINOID EFFECTS AND CANNABIMIMETIC DRUGS$137,830
K05 · FY2000 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$84,712
R37 · FY2000 · DA
MOLECULAR BASIS OF CANNABINOID ACITIVITY$75,000
R37 · FY2000 · DA
THE CANNABINOID RECEPTOR AS A THERAPEUTIC TARGET$8,199
P41 · FY2000 · RR
MOLECULAR BASIS OF CANNABINOID ACITIVITY$8,018
R37 · FY2000 · DA
TRAINING IN MEDICATIONS DEVELOPMENT FOR DRUGS OF ABUSE$4,040
T32 · FY2000 · DA